Nifty 50
- Cipla₹1,426.8038.80 (2.80%)
- Titan Company₹4,712.10-195.90 (-3.99%)
- Trent₹3,206.2029.90 (0.94%)
- Adani Enterprises₹2,681.40-63.70 (-2.32%)
- Sun Pharmaceutical₹1,88313.00 (0.70%)
- Hindalco Industries₹906.30-21.45 (-2.31%)
- SBI₹1,115.506.90 (0.62%)
- Asian Paints₹2,571.60-53.40 (-2.03%)
- Maruti Suzuki₹12,70176.00 (0.60%)
- HDFC Life Insurance ₹583.45-11.60 (-1.95%)
- UltraTech Cement₹12,36171.00 (0.58%)
- Bajaj Finance₹1,101.15-19.95 (-1.78%)
- Apollo Hospitals₹8,75542.50 (0.49%)
- Tata Motors PV₹254.85-4.35 (-1.68%)
- ONGC₹224.300.78 (0.35%)
- Eicher Motors₹7,715.50-112.50 (-1.44%)
- Tata Consumer ₹1,1163.60 (0.32%)
- JSW Steel₹1,313.20-18.80 (-1.41%)
- L&T₹4,1648.50 (0.20%)
- InterGlobe Aviation₹5,535.80-75.20 (-1.34%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Cipla's InvaGen Facility Receives USFDA No Action Indicated Status; Shares Rise Marginally
Authored By HDFC SKY | Published at: Nov 18, 2026 10:16 AM IST
Cipla Limited has received a No Action Indicated (NAI) classification from the US Food and Drug Administration (USFDA) for its InvaGen Pharmaceuticals manufacturing facility in Hauppauge, New York. The inspection was conducted between October 19 and 22, 2026. Cipla shares traded marginally higher around ₹1,390 during morning trading on November 18, 2026.

Open Free Demat Account
Mumbai, November 18: Cipla Limited has announced that the US Food and Drug Administration (USFDA) has classified its InvaGen Pharmaceuticals manufacturing facility in Hauppauge, Long Island, New York, as No Action Indicated (NAI). The classification follows a regulatory inspection conducted at the facility in October 2026. Cipla disclosed the development to stock exchanges on November 17, 2026. The regulatory outcome is positive for the company’s US manufacturing operations, as the inspection concluded without the need for regulatory action.
USFDA Classifies Cipla’s InvaGen Facility Inspection as No Action Indicated
According to Cipla’s regulatory filing, the USFDA inspected the manufacturing facility of InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of the company, from October 19 to October 22, 2026. The USFDA communicated its final inspection classification on November 17, confirming the facility’s No Action Indicated status. An NAI classification means that the regulator did not identify conditions requiring regulatory action following the inspection. It is generally considered a favourable outcome for pharmaceutical manufacturing facilities operating under USFDA oversight. The classification provides regulatory clarity for Cipla’s InvaGen manufacturing operations in the United States. However, it does not represent approval of any new drug or product. Cipla had previously informed stock exchanges about the completion of the inspection on October 23, 2026. The latest disclosure confirms the regulatory outcome of that inspection. The company’s latest quarterly results, announced on October 27, provide additional financial context. Cipla reported consolidated revenue from operations of ₹7,404 crore for Q2 FY27, compared with ₹7,589 crore in the corresponding quarter last year. EBITDA stood at ₹1,388 crore, while profit after tax was ₹878 crore.
Stock Market Snapshot
Cipla share price were trading at approximately ₹1,390 on Wednesday, November 18, 2026, up around ₹2 or 0.14% from the previous NSE closing price of ₹1,388 on November 17. The stock initially traded near ₹1,390 before declining towards ₹1,382.50 during morning trading. It subsequently recovered and moved back towards ₹1,390. The supplied chart extends to approximately 9:53 AM IST. Since the exact last-traded price and timestamp are not displayed, the quoted figures are approximate. The positive USFDA inspection outcome provides a favourable regulatory development for Cipla, although its direct contribution to the marginal share price increase has not been independently established.

About Cipla
Cipla Limited is a Mumbai-based pharmaceutical company engaged in the development, manufacturing and marketing of medicines across multiple therapeutic categories. The company has a presence in India, North America, South Africa and other international markets. Its portfolio includes respiratory medicines, anti-infectives, cardiovascular treatments and other pharmaceutical products. InvaGen Pharmaceuticals Inc. is Cipla’s wholly owned subsidiary in the United States.
Conclusion
Cipla’s InvaGen manufacturing facility in New York has received a favourable regulatory outcome following the USFDA’s October 2026 inspection. The No Action Indicated classification confirms that no regulatory action was required following the inspection, providing clarity for the company’s US manufacturing operations. Cipla shares traded marginally higher during morning trading on November 18, although the direct impact of the regulatory announcement on the stock price remains unconfirmed.
Source:
- https://www.nseindia.in/get-quote/equity/CIPLA/Cipla-Limited
Disclaimer
The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.
More CIPLA News
Open Free Demat Account
₹1,426.80
By signing up I certify terms, conditions & privacy policy

Join Us
Add as preferred source on Google

















